Author

W. Farnaby

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 2 Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Research Focus:cancer & tumor microenvironment· 1 Organism:human· 1 Assay:protein structure· 1 Research Focus:protein structure prediction· 1 Approach:statistical model· 1

Frequent Co-Authors

A. Ciulli· 4 shared C. Whitworth· 3 shared A. B. Frost· 2 shared A. Wijaya· 2 shared C. Kofink· 2 shared D. Zollman· 2 shared E. Diers· 2 shared M. Koegl· 2 shared

Activity by Year

2019-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersBiochemistry

A. Ciulli

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Design of a Cereblon construct for crystallographic and biophysical studies of protein degraders

A. Kroupova, V. A. Spiteri, H. Furihata, D. Darren, S. Ramachandran, Z. Rutter, S. Chakraborti, K. Haubrich, J. Pethe, D. Gonzales, A. Wijaya, M. Rodriguez-Rios, D. M. Lynch, W. Farnaby, M. Nakasone, , A. Ciulli

The paper introduces CRBNmidi, a Cereblon construct that enables high-resolution structural and biophysical studies of degraders without requiring DDB1 co-expression.

Nature Communications · Oct 15, 2024Peer-reviewedBiochemistry

Confounding factors in targeted degradation of short-lived proteins

V. Vetma, L. C. Perez, J. Elias, A. Stingu, A. Kombara, T. Gmaschitz, N. Braun, T. Ciftci, G. Dahmann, E. Diers, T. Gerstberger, P. Greb, G. Kidd, C. Kofink, I. Puoti, , M. Koegl

This study shows that the natural half-life of a target protein significantly affects degradation by degrader agents and highlights confounding factors in screening for protein degraders.

bioRxiv · Feb 19, 2024Cancer Biology

Targeting cancer with small molecule pan-KRAS degraders

J. Popow, W. Farnaby, A. Gollner, C. Kofink, G. Fischer, M. Wurm, D. Zollman, A. Wijaya, N. Mischerikow, C. Hasenoehrl, P. Prokofeva, H. Arnhof, S. Arce-Solano, S. Bell, G. Boeck, , A. Ciulli

A single small molecule degrader targets 13 out of 17 prevalent oncogenic KRAS alleles, inhibiting growth of KRAS-driven cancer cell lines and inducing tumour regression in vivo.

bioRxiv · Oct 24, 2023Pharmacology & Toxicology

SPR-measured dissociation kinetics of PROTAC ternary complexes influence target degradation rate

M. J. Roy, S. Winkler, S. J. Hughes, C. Whitworth, M. Galant, W. Farnaby, K. Rumpel, A. Ciulli

This paper develops an SPR-based assay to measure PROTAC ternary complex dissociation kinetics and shows that differences in off-rates correlate with target degradation efficiency.

bioRxiv · Feb 3, 2019Biochemistry